WO1995001997A1 - ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME - Google Patents

ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME Download PDF

Info

Publication number
WO1995001997A1
WO1995001997A1 PCT/US1994/007659 US9407659W WO9501997A1 WO 1995001997 A1 WO1995001997 A1 WO 1995001997A1 US 9407659 W US9407659 W US 9407659W WO 9501997 A1 WO9501997 A1 WO 9501997A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
seq
sequence
light chain
amino acid
Prior art date
Application number
PCT/US1994/007659
Other languages
English (en)
Inventor
Peter Ronald Young
Mitchell Stuart Gross
Zdenka Ludmila Jonak
Timothy Wayne Theisen
Mark Robert Hurle
Jeffrey Richard Jackson
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of WO1995001997A1 publication Critical patent/WO1995001997A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à des anticorps monoclonaux et recombinants, chimères et humanisés, dirigés contre des épitopes se trouvant sur la protéine humaine Interleukine-1β (IL-1β), à des compositions utilisant ces anticorps, ainsi qu'à des procédés destinés à leur préparation et à leur utilisation.
PCT/US1994/007659 1993-07-09 1994-07-07 ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME WO1995001997A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9053493A 1993-07-09 1993-07-09
US08/090,534 1993-07-09
US20619094A 1994-03-04 1994-03-04
US08/206,190 1994-03-04

Publications (1)

Publication Number Publication Date
WO1995001997A1 true WO1995001997A1 (fr) 1995-01-19

Family

ID=26782383

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/007659 WO1995001997A1 (fr) 1993-07-09 1994-07-07 ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME

Country Status (1)

Country Link
WO (1) WO1995001997A1 (fr)

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997015327A1 (fr) * 1995-10-25 1997-05-01 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procede de traitement de la colite chronique a l'aide d'anticorps contre il-12
EP0770628A1 (fr) * 1994-07-13 1997-05-02 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
EP0813423A1 (fr) * 1995-01-23 1997-12-29 Xenotech Incorporated Procede visant a inhiber l'osteolyse et les metastases
WO1999024615A2 (fr) * 1997-11-07 1999-05-20 Medical Science Systems, Inc. Diagnostics et therapies des maladies obstructives chroniques des voies respiratoires
WO2000037679A2 (fr) * 1998-10-30 2000-06-29 Interleukin Genetics, Inc. Diagnostic et traitement d'une septicemie
US6140047A (en) * 1997-11-07 2000-10-31 Interleukin Genetics, Inc. Method and kit for predicting susceptibility to asthma
WO2001053353A2 (fr) * 2000-01-21 2001-07-26 Novartis Ag Anticorps anti-interleukine 1$g(b) humain
WO2001068705A2 (fr) 2000-03-16 2001-09-20 Amgen Inc. Molecules du type recepteur de l'interleukine 17 et leurs utilisations
WO2002016436A2 (fr) * 2000-08-22 2002-02-28 Novartis Ag ANTICORPS DE LA IL-1β HUMAINE
WO2003010282A3 (fr) * 2001-07-26 2004-02-12 Lilly Co Eli Anticorps vis-a-vis de l'interleukine 1 beta (il-1$g(b))
US6746839B1 (en) 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
WO2004072116A2 (fr) * 2003-02-13 2004-08-26 Celltech R & D Limited Molecules d'anticorps possedant une specificite pour il-1? humain
WO2004067568A3 (fr) * 2003-01-24 2004-10-07 Applied Molecular Evolution Antagonistes de l'il-1 beta humaine
EP1563083A2 (fr) * 2001-12-26 2005-08-17 Molecular Staging, Inc. Utilisation de cytokines secretees par les cellules dendritiques
WO2007050607A2 (fr) * 2005-10-26 2007-05-03 Novartis Ag Nouvelle utilisation de composes il-1beta
WO2007096058A1 (fr) 2006-02-21 2007-08-30 Bayer Cropscience Ag Cétoénols cycliques à substitution cycloalkyl-phényle
DE102007009957A1 (de) 2006-12-27 2008-07-03 Bayer Cropscience Ag Verfahren zur verbesserten Nutzung des Produktionsptentials transgener Pflanzen
EP1992636A2 (fr) 1999-11-12 2008-11-19 Amgen Inc. Procédé pour la correction d'un mauvais repliement de bisulfure dans les molécules Fc
EP2002846A2 (fr) 1996-12-06 2008-12-17 Amgen Inc. Thérapie combinée utilisant un inhibiteur IL-1 pour traiter les maladies liées au IL-1
US7531166B2 (en) 2005-06-21 2009-05-12 Xoma Technology, Ltd. IL-1β binding antibodies and fragments thereof
US7566772B2 (en) 2005-01-26 2009-07-28 Amgen Fremont Inc. Antibodies against interleukin-1β
EP2087908A1 (fr) 2001-06-26 2009-08-12 Amgen, Inc. Anticorps opgl
EP2098537A2 (fr) 2008-03-05 2009-09-09 4-Antibody AG Identification de protéines de liaison spécifiques à des antigènes ou à des ligands
WO2009115262A1 (fr) 2008-03-19 2009-09-24 Bayer Cropscience Ag Tétramates spirocycliques à substitution 4'4'-dioxaspiro
US7695718B2 (en) 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
EP2196476A1 (fr) 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
EP2213685A1 (fr) 2002-09-06 2010-08-04 Amgen Inc. Anticorps monoclonal anti-IL-1R1 thérapeutique
WO2010086095A1 (fr) 2009-01-29 2010-08-05 Bayer Cropscience Ag Procédé pour l'utilisation améliorée du potentiel de production de plantes transgéniques
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
EP2266399A1 (fr) 2006-05-12 2010-12-29 Bayer CropScience AG Utilisation de dérivés d'acide tétramique destinés à lutter contre les insectes de la famille des chrysomèles (Chrysomelidae)
EP2314289A1 (fr) 2005-10-31 2011-04-27 Braincells, Inc. Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
WO2011063115A1 (fr) 2009-11-19 2011-05-26 Braincells Inc. Combinaison d'un agent nootropique avec un ou plusieurs agents neurogènes ou à effet neurogène par synergie pour stimuler ou intensifier la neurogenèse
WO2011061336A1 (fr) 2009-11-23 2011-05-26 4-Antibody Ag Particules de vecteur rétroviral et procédés pour leur génération et leur utilisation
WO2011091033A1 (fr) 2010-01-20 2011-07-28 Braincells, Inc. Modulation de la neurogenèse par des agents ppar
EP2366715A2 (fr) 2005-11-14 2011-09-21 Amgen Inc. Molécules chimère d'anticorps anti-RANKL et de PTH/PTHRP
EP2377531A2 (fr) 2006-05-09 2011-10-19 Braincells, Inc. Neurogénèse par modulation de l'angiotensine
EP2377553A1 (fr) 2006-04-14 2011-10-19 Novartis AG Utilisation d'anticorps IL-1 pour traiter les troubles ophtalmiques
EP2377530A2 (fr) 2005-10-21 2011-10-19 Braincells, Inc. Modulation de neurogénèse par inhibition PDE
EP2468302A1 (fr) 2007-05-29 2012-06-27 Novartis AG Nouvelles indications pour une thérapie anti-IL-1-bêta
WO2012034039A3 (fr) * 2010-09-10 2012-07-26 Apexigen, Inc. Anticorps anti-il-1 bêta et leurs procédés d'utilisation
US8247351B2 (en) 2005-12-13 2012-08-21 Bayer Cropscience Ag Insecticidal compositions having improved effect
EP2488201A1 (fr) * 2009-10-15 2012-08-22 Abbott Laboratories Protéines de liaison à l'il-1
US20120213787A1 (en) * 2009-07-14 2012-08-23 Inusha De Silva Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
US8377429B2 (en) 2008-09-05 2013-02-19 Xoma Technology Ltd. Methods for improvement of beta cell function with anti-IL-1β antibodies or fragments thereof
WO2013096516A1 (fr) 2011-12-19 2013-06-27 Xoma Technology Ltd. Méthodes de traitement de l'acné
WO2013106547A1 (fr) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
JP2013537415A (ja) * 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
US8551487B2 (en) 2010-05-07 2013-10-08 Xoma Technology, Ltd. Methods for the treatment of IL-1β related conditions
US8586714B2 (en) 2009-09-01 2013-11-19 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
US8637029B2 (en) 2007-12-20 2014-01-28 Xoma Technology Ltd. Methods for the treatment of gout
US8664367B2 (en) 2010-05-14 2014-03-04 Abbvie, Inc. IL-I binding proteins
US8716450B2 (en) 2009-10-15 2014-05-06 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8722855B2 (en) 2009-10-28 2014-05-13 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
US8987418B2 (en) 2013-03-15 2015-03-24 Abbvie Inc. Dual specific binding proteins directed against IL-1β and/or IL-17
US9029508B2 (en) 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9035027B2 (en) * 2008-06-03 2015-05-19 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9045551B2 (en) 2012-11-01 2015-06-02 Abbvie Inc. Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9109026B2 (en) 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
WO2015184099A1 (fr) 2014-05-28 2015-12-03 4-Antibody Ag Anticorps anti-gitr et leurs procédés d'utilisation
EP3001905A1 (fr) 2006-06-16 2016-04-06 Bayer Intellectual Property GmbH Combinaisons d'agents actifs a proprietes insecticides et acaricides
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
US9840554B2 (en) 2015-06-15 2017-12-12 Abbvie Inc. Antibodies against platelet-derived growth factor (PDGF)
US9970944B2 (en) 2004-02-17 2018-05-15 Merck Sharp & Dohme Corp. Methods of modulating cytokine activity; related reagents
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2020035482A1 (fr) 2018-08-13 2020-02-20 Iltoo Pharma Combinaison d'interleukine 2 et d'un inhibiteur de l'interleukine 1, conjugués et utilisations thérapeutiques de celle-ci
US10836830B2 (en) 2015-12-02 2020-11-17 Agenus Inc. Antibodies and methods of use thereof
CN113383016A (zh) * 2018-11-07 2021-09-10 三生国健药业（上海）股份有限公司 结合人IL-1β的抗体、其制备方法和用途
US11359028B2 (en) 2016-11-09 2022-06-14 Agenus Inc. Anti-OX40 antibodies and anti-GITR antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0267611A2 (fr) * 1986-11-13 1988-05-18 Otsuka Pharmaceutical Co., Ltd. Anticorps contre l'interleukine-1
EP0364778A1 (fr) * 1988-10-01 1990-04-25 Otsuka Pharmaceutical Co., Ltd. Anticorps contre l'interleukine-1 bêta
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
WO1991009967A1 (fr) * 1989-12-21 1991-07-11 Celltech Limited Anticorps humanises

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
EP0267611A2 (fr) * 1986-11-13 1988-05-18 Otsuka Pharmaceutical Co., Ltd. Anticorps contre l'interleukine-1
EP0364778A1 (fr) * 1988-10-01 1990-04-25 Otsuka Pharmaceutical Co., Ltd. Anticorps contre l'interleukine-1 bêta
WO1991009967A1 (fr) * 1989-12-21 1991-07-11 Celltech Limited Anticorps humanises

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOTECHNIQUES, Volume 5, Number 7, issued October 1987, GAFFNEY et al., "Enzyme Linked Immunoassay with Monoclonal Antibody For Human Interleukin-1-beta", pages 652-659. *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 268, Number 13, issued 05 May 1993, SIMON et al., "Mapping of Neutralizing Epitopes and the Receptor Binding Site of Human Interleukin 1beta", pages 9771-9779. *

Cited By (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0770628A4 (fr) * 1994-07-13 2004-10-27 Chugai Pharmaceutical Co Ltd Anticorps humain reconstitue contre l'interleukine-8 humaine
EP0770628A1 (fr) * 1994-07-13 1997-05-02 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
EP0813423A1 (fr) * 1995-01-23 1997-12-29 Xenotech Incorporated Procede visant a inhiber l'osteolyse et les metastases
EP0813423A4 (fr) * 1995-01-23 1998-04-22 Xenotech Inc Procede visant a inhiber l'osteolyse et les metastases
WO1997015327A1 (fr) * 1995-10-25 1997-05-01 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procede de traitement de la colite chronique a l'aide d'anticorps contre il-12
AU710282B2 (en) * 1995-10-25 1999-09-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of treating established colitis using antibodies against IL-12
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
JP2008169199A (ja) * 1995-10-25 2008-07-24 Government Of The Us Of America As Represent By Secretary Of Department Of Health & Human Services Ｉｌ−１２に対する抗体を使用する、確立した結腸炎を処置する方法
EP2002846A2 (fr) 1996-12-06 2008-12-17 Amgen Inc. Thérapie combinée utilisant un inhibiteur IL-1 pour traiter les maladies liées au IL-1
WO1999024615A2 (fr) * 1997-11-07 1999-05-20 Medical Science Systems, Inc. Diagnostics et therapies des maladies obstructives chroniques des voies respiratoires
WO1999024615A3 (fr) * 1997-11-07 1999-09-16 Medical Science Sys Inc Diagnostics et therapies des maladies obstructives chroniques des voies respiratoires
US6140047A (en) * 1997-11-07 2000-10-31 Interleukin Genetics, Inc. Method and kit for predicting susceptibility to asthma
US6746839B1 (en) 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US6551785B2 (en) 1998-10-30 2003-04-22 Interleukin Genetics, Inc. Diagnostics for bacterial meningitus
US6251598B1 (en) 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
WO2000037679A3 (fr) * 1998-10-30 2001-01-11 Interleukin Genetics Inc Diagnostic et traitement d'une septicemie
WO2000037679A2 (fr) * 1998-10-30 2000-06-29 Interleukin Genetics, Inc. Diagnostic et traitement d'une septicemie
EP1992636A2 (fr) 1999-11-12 2008-11-19 Amgen Inc. Procédé pour la correction d'un mauvais repliement de bisulfure dans les molécules Fc
CN1395581B (zh) * 2000-01-21 2010-10-13 诺瓦提斯公司 重组人白细胞介素-1β抗体
WO2001053353A3 (fr) * 2000-01-21 2002-04-04 Novartis Ag Anticorps anti-interleukine 1$g(b) humain
CZ302738B6 (cs) * 2000-01-21 2011-10-12 Novartis Ag Protilátka proti IL-1beta tvorená molekulou vázající IL-1beta, tato molekula pro použití jako lécivo, použití této molekuly pro výrobu léciva, odpovídající DNA konstrukty a expresní vektor, zpusob prípravy uvedené molekuly a farmaceutická kompozice o
WO2001053353A2 (fr) * 2000-01-21 2001-07-26 Novartis Ag Anticorps anti-interleukine 1$g(b) humain
US7491392B2 (en) 2000-01-21 2009-02-17 Novartis Ag Antibodies to human IL-1β
WO2001068705A2 (fr) 2000-03-16 2001-09-20 Amgen Inc. Molecules du type recepteur de l'interleukine 17 et leurs utilisations
WO2002016436A3 (fr) * 2000-08-22 2002-06-20 Novartis Ag ANTICORPS DE LA IL-1β HUMAINE
WO2002016436A2 (fr) * 2000-08-22 2002-02-28 Novartis Ag ANTICORPS DE LA IL-1β HUMAINE
KR100910789B1 (ko) * 2000-08-22 2009-08-04 노파르티스 아게 인간 ＩＬ-1β에 대한 항체
US8273350B2 (en) 2000-08-22 2012-09-25 Novartis Ag Antibodies to human IL-1β
US7993878B2 (en) 2000-08-22 2011-08-09 Novartis Ag Antibodies to human IL-1β
US7446175B2 (en) 2000-08-22 2008-11-04 Novartis Ag Antibodies to human IL-1β
JP2004506448A (ja) * 2000-08-22 2004-03-04 ノバルティス　アクチエンゲゼルシャフト ヒトＩＬ−１βに対する抗体
EP3492100A1 (fr) 2001-06-26 2019-06-05 Amgen Inc. Anticorps pour opgl
EP2087908A1 (fr) 2001-06-26 2009-08-12 Amgen, Inc. Anticorps opgl
WO2003010282A3 (fr) * 2001-07-26 2004-02-12 Lilly Co Eli Anticorps vis-a-vis de l'interleukine 1 beta (il-1$g(b))
EP1563083A2 (fr) * 2001-12-26 2005-08-17 Molecular Staging, Inc. Utilisation de cytokines secretees par les cellules dendritiques
EP1563083A4 (fr) * 2001-12-26 2006-03-22 Molecular Staging Inc Utilisation de cytokines secretees par les cellules dendritiques
EP2277543A1 (fr) 2002-09-06 2011-01-26 Amgen, Inc Anticorps monoclonal anti-IL-1R1 thérapeutique
EP3020414A1 (fr) 2002-09-06 2016-05-18 Amgen, Inc Anticorps monoclonal anti-il-1r1 thérapeutique
EP2213685A1 (fr) 2002-09-06 2010-08-04 Amgen Inc. Anticorps monoclonal anti-IL-1R1 thérapeutique
WO2004067568A3 (fr) * 2003-01-24 2004-10-07 Applied Molecular Evolution Antagonistes de l'il-1 beta humaine
JP2010143929A (ja) * 2003-01-24 2010-07-01 Applied Molecular Evolution Inc ヒトＩＬ−１βアンタゴニスト
US7541033B2 (en) 2003-01-24 2009-06-02 Applied Molecular Evolution, Inc. Humanized anti-IL-1β antibodies
JP2007531509A (ja) * 2003-01-24 2007-11-08 アプライド モレキュラー エボリューション，インコーポレイテッド ヒトＩＬ−１βアンタゴニスト
US7714120B2 (en) 2003-01-24 2010-05-11 Applied Molecule Evolution, Inc. Humanized anti-IL-1 beta antibodies
AU2004207741B2 (en) * 2003-01-24 2011-02-10 Applied Molecular Evolution, Inc Human IL-1 beta antagonists
WO2004072116A2 (fr) * 2003-02-13 2004-08-26 Celltech R & D Limited Molecules d'anticorps possedant une specificite pour il-1? humain
WO2004072116A3 (fr) * 2003-02-13 2004-11-18 Celltech R&D Ltd Molecules d'anticorps possedant une specificite pour il-1? humain
US8465744B2 (en) 2003-02-13 2013-06-18 Ucb Pharma S.A. Method of treating inflammation by administering human IL-1B antibodies
EP2287193A1 (fr) 2003-02-13 2011-02-23 UCB Pharma, S.A. Molécules d'anticorps possédant une spécificité pour IL-1 beta humain
AU2004210776B2 (en) * 2003-02-13 2011-04-07 Ucb Pharma S.A. Antibody molecules having specificity for human IL-1beta
US7608694B2 (en) 2003-02-13 2009-10-27 Ucb Pharma S.A. Antibody molecules having specificity for human IL-1β
JP4668896B2 (ja) * 2003-02-13 2011-04-13 ユセベ ファルマ ソシエテ アノニム ヒトＩＬ−１βに対する特異性を有する抗体分子
JP2010246553A (ja) * 2003-02-13 2010-11-04 Ucb Pharma Sa ヒトＩＬ−１βに対する特異性を有する抗体分子
JP2007515925A (ja) * 2003-02-13 2007-06-21 セルテック アール アンド ディ リミテッド ヒトＩＬ−１βに対する特異性を有する抗体分子
US9970944B2 (en) 2004-02-17 2018-05-15 Merck Sharp & Dohme Corp. Methods of modulating cytokine activity; related reagents
US7566772B2 (en) 2005-01-26 2009-07-28 Amgen Fremont Inc. Antibodies against interleukin-1β
US7964193B2 (en) 2005-01-26 2011-06-21 Amgen Fremont Inc. Antibodies against interleukin-1 β
US7531166B2 (en) 2005-06-21 2009-05-12 Xoma Technology, Ltd. IL-1β binding antibodies and fragments thereof
US9206252B2 (en) 2005-06-21 2015-12-08 Xoma (Us) Llc Pharmaceutical compositions comprising IL-1B binding antibodies and fragments thereof
US7943121B2 (en) 2005-06-21 2011-05-17 Xoma Technology Ltd. IL-1β binding antibodies and fragments thereof
US8377442B2 (en) 2005-06-21 2013-02-19 Xoma Technology Ltd. Method of treating inflammatory eye disease with IL-1β binding antibodies
US7744866B2 (en) 2005-06-21 2010-06-29 Xoma Technology Ltd. IL-1β binding antibodies and binding fragments thereof
US7744865B2 (en) 2005-06-21 2010-06-29 Xoma Technology Ltd. IL1-β Binding antibodies and fragments thereof
US7829094B2 (en) 2005-06-21 2010-11-09 Xoma Technology Ltd. Method of treating an IL-1 related cancer
US7829093B2 (en) 2005-06-21 2010-11-09 Xoma Technology Ltd. Method of treating an IL-1 related autoimmune disease or condition
US7988968B2 (en) 2005-06-21 2011-08-02 Xoma Technology Ltd. Method of treating an IL-1 related coronary condition
US7582742B2 (en) 2005-06-21 2009-09-01 Xoma Technology Ltd. Method of treating or preventing an IL-1 related disease or condition
US7695717B2 (en) 2005-06-21 2010-04-13 Xoma Technology Ltd. Method of treating an IL-1 related inflammatory disease or condition
EP2377530A2 (fr) 2005-10-21 2011-10-19 Braincells, Inc. Modulation de neurogénèse par inhibition PDE
WO2007050607A2 (fr) * 2005-10-26 2007-05-03 Novartis Ag Nouvelle utilisation de composes il-1beta
EP4218815A3 (fr) * 2005-10-26 2024-03-27 Novartis AG Utilisation d' anticorps anti il-1beta
US8409576B2 (en) 2005-10-26 2013-04-02 Novartis Ag Use of IL-1beta compounds
WO2007050607A3 (fr) * 2005-10-26 2007-06-28 Novartis Ag Nouvelle utilisation de composes il-1beta
RU2468817C2 (ru) * 2005-10-26 2012-12-10 Новартис Аг НОВОЕ ПРИМЕНЕНИЕ СОЕДИНЕНИЙ ИЛ-1β
US8105587B2 (en) 2005-10-26 2012-01-31 Novartis Ag Methods of treating arthritis using IL-1β binding molecules
US9649377B2 (en) 2005-10-26 2017-05-16 Novartis Ag Methods of using IL-1β compounds to treat familial mediterranean fever (FMF)
EP2332577A1 (fr) 2005-10-26 2011-06-15 Novartis AG Nouvelle utilisation de composés IL-1 béta
AU2006306280B2 (en) * 2005-10-26 2010-06-17 Novartis Ag Novel use of IL-1beta compounds
EP3332807A3 (fr) * 2005-10-26 2018-06-20 Novartis AG Utilisation d' anticorps anti il-1beta
NO345140B1 (no) * 2005-10-26 2020-10-12 Novartis Ag Anvendelse av humane IL-1beta bindende antistoffer og farmasøytiske sammensetninger inneholdende slike, for fremstilling av et medikament for behandling av juvenil reumatoid artritt
EP2314289A1 (fr) 2005-10-31 2011-04-27 Braincells, Inc. Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
EP2366715A2 (fr) 2005-11-14 2011-09-21 Amgen Inc. Molécules chimère d'anticorps anti-RANKL et de PTH/PTHRP
EP2816060A1 (fr) 2005-11-14 2014-12-24 Amgen Inc. Molécules chimère d'anticorps PTH/PTHRP de rang 1
US8247351B2 (en) 2005-12-13 2012-08-21 Bayer Cropscience Ag Insecticidal compositions having improved effect
WO2007096058A1 (fr) 2006-02-21 2007-08-30 Bayer Cropscience Ag Cétoénols cycliques à substitution cycloalkyl-phényle
EP2186805A1 (fr) 2006-02-21 2010-05-19 Bayer CropScience AG Kétoénoles cycliques substitués par cycloalkyl-phényle
EP2186791A1 (fr) 2006-02-21 2010-05-19 Bayer CropScience AG Kétoénoles cycliques substitués par cycloalkyl-phényle
EP2184275A1 (fr) 2006-02-21 2010-05-12 Bayer CropScience AG Kétoénoles cycliques substitués par cycloalkyl-phényle
EP2377553A1 (fr) 2006-04-14 2011-10-19 Novartis AG Utilisation d'anticorps IL-1 pour traiter les troubles ophtalmiques
EP2382975A2 (fr) 2006-05-09 2011-11-02 Braincells, Inc. Neurogénèse par modulation d'angiotensine
EP2377531A2 (fr) 2006-05-09 2011-10-19 Braincells, Inc. Neurogénèse par modulation de l'angiotensine
EP2289318A1 (fr) 2006-05-12 2011-03-02 Bayer CropScience AG Utilisation de dérivés d'acide tétramique destinés à lutter contre les insectes de la famille des Tortricidae
EP2277379A1 (fr) 2006-05-12 2011-01-26 Bayer CropScience AG Utilisation de dérivés d'acide tétramique destinés à lutter contre les insectes de la famille des mouches à fruit (Tephritidae)
EP2266399A1 (fr) 2006-05-12 2010-12-29 Bayer CropScience AG Utilisation de dérivés d'acide tétramique destinés à lutter contre les insectes de la famille des chrysomèles (Chrysomelidae)
EP2277380A1 (fr) 2006-05-12 2011-01-26 Bayer CropScience AG Utilisation de dérivés d'acide tétramique destinés à lutter contre les insectes de la famille des curculionidés (Curculionidae)
EP2289319A1 (fr) 2006-05-12 2011-03-02 Bayer CropScience AG Utilisation de dérivés d'acide tétramique destinés à lutter contre les insectes de la famille des tenthrèdes (Tenthredinidae)
EP2277377A1 (fr) 2006-05-12 2011-01-26 Bayer CropScience AG Utilisation de dérivés d'acide tétramique destinés à lutter contre les insectes de la famille des Thripidae
EP2289317A1 (fr) 2006-05-12 2011-03-02 Bayer CropScience AG Utilisation de dérivés d'acide tétramique destinés à lutter contre les insectes de la famille des Cecidomyiidae
EP2277378A1 (fr) 2006-05-12 2011-01-26 Bayer CropScience AG Utilisation de dérivés d'acide tétramique destinés à lutter contre les insectes de la famille des mouches (Diptera)
EP2289316A1 (fr) 2006-05-12 2011-03-02 Bayer CropScience AG Utilisation de dérivés d'acide tétramique destinés à lutter contre les insectes de la famille des cicadelles (Cicadellidae)
EP3001905A1 (fr) 2006-06-16 2016-04-06 Bayer Intellectual Property GmbH Combinaisons d'agents actifs a proprietes insecticides et acaricides
EP3124045A2 (fr) 2006-12-20 2017-02-01 Xoma (Us) Llc Traitement de maladies apparentées il-1 beta
US7695718B2 (en) 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
US8586036B2 (en) 2006-12-20 2013-11-19 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
US9163082B2 (en) 2006-12-20 2015-10-20 Xoma (Us) Llc Methods for the treatment of IL-1β related diseases
US8101166B2 (en) 2006-12-20 2012-01-24 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
DE102007009957A1 (de) 2006-12-27 2008-07-03 Bayer Cropscience Ag Verfahren zur verbesserten Nutzung des Produktionsptentials transgener Pflanzen
EP2468301A1 (fr) 2007-05-29 2012-06-27 Novartis AG Nouvelles indications pour une thérapie anti-IL-1-bêta
EP2468302A1 (fr) 2007-05-29 2012-06-27 Novartis AG Nouvelles indications pour une thérapie anti-IL-1-bêta
EP4177268A2 (fr) 2007-05-29 2023-05-10 Novartis AG Nouvelles indications pour une thérapie anti-il-1-bêta
EP2851373A1 (fr) 2007-12-20 2015-03-25 Xoma (Us) Llc Procédés pour le traitement de la goutte
US8637029B2 (en) 2007-12-20 2014-01-28 Xoma Technology Ltd. Methods for the treatment of gout
EP2098537A2 (fr) 2008-03-05 2009-09-09 4-Antibody AG Identification de protéines de liaison spécifiques à des antigènes ou à des ligands
US8748353B2 (en) 2008-03-05 2014-06-10 4-Antibody Ag Identification of antigen or ligand-specific binding proteins
US10502745B2 (en) 2008-03-05 2019-12-10 Agenus Inc. Identification of antigen- or ligand-specific binding proteins
US9593327B2 (en) 2008-03-05 2017-03-14 Agenus Inc. Identification of antigen or ligand-specific binding proteins
US8716194B2 (en) 2008-03-05 2014-05-06 4-Antibody Ag Identification of antigen or ligand-specific binding proteins
WO2009115262A1 (fr) 2008-03-19 2009-09-24 Bayer Cropscience Ag Tétramates spirocycliques à substitution 4'4'-dioxaspiro
US9029508B2 (en) 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9035027B2 (en) * 2008-06-03 2015-05-19 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9109026B2 (en) 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
US8377429B2 (en) 2008-09-05 2013-02-19 Xoma Technology Ltd. Methods for improvement of beta cell function with anti-IL-1β antibodies or fragments thereof
EP2196476A1 (fr) 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
WO2010086095A1 (fr) 2009-01-29 2010-08-05 Bayer Cropscience Ag Procédé pour l'utilisation améliorée du potentiel de production de plantes transgéniques
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
US20120213787A1 (en) * 2009-07-14 2012-08-23 Inusha De Silva Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
US9028817B2 (en) * 2009-07-14 2015-05-12 Glaxo Group Limited Stable anti-TNFR1 polypeptides, antibody variable domains and antagonists
US8586714B2 (en) 2009-09-01 2013-11-19 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
EP2488201A1 (fr) * 2009-10-15 2012-08-22 Abbott Laboratories Protéines de liaison à l'il-1
EP2488201A4 (fr) * 2009-10-15 2013-12-25 Abbvie Inc Protéines de liaison à l'il-1
US8716450B2 (en) 2009-10-15 2014-05-06 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8722855B2 (en) 2009-10-28 2014-05-13 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2011063115A1 (fr) 2009-11-19 2011-05-26 Braincells Inc. Combinaison d'un agent nootropique avec un ou plusieurs agents neurogènes ou à effet neurogène par synergie pour stimuler ou intensifier la neurogenèse
WO2011061336A1 (fr) 2009-11-23 2011-05-26 4-Antibody Ag Particules de vecteur rétroviral et procédés pour leur génération et leur utilisation
WO2011091033A1 (fr) 2010-01-20 2011-07-28 Braincells, Inc. Modulation de la neurogenèse par des agents ppar
US9139646B2 (en) 2010-05-07 2015-09-22 Xoma (Us) Llc Methods for the treatment of uveitis with IL-1β binding antibodies
US8551487B2 (en) 2010-05-07 2013-10-08 Xoma Technology, Ltd. Methods for the treatment of IL-1β related conditions
US9441038B2 (en) 2010-05-14 2016-09-13 Abbvie Inc. IL-1 binding proteins
US9447183B2 (en) 2010-05-14 2016-09-20 Abbvie Inc. IL-1 binding proteins
US8841417B2 (en) 2010-05-14 2014-09-23 Abbvie Inc. IL-1 binding proteins
KR101848225B1 (ko) 2010-05-14 2018-04-12 애브비 인코포레이티드 Ｉｌ－１ 결합 단백질
US8664367B2 (en) 2010-05-14 2014-03-04 Abbvie, Inc. IL-I binding proteins
KR101539683B1 (ko) * 2010-05-14 2015-07-30 애브비 인코포레이티드 Ｉｌ－１ 결합 단백질
KR101539684B1 (ko) * 2010-05-14 2015-07-27 애브비 인코포레이티드 Ｉｌ－１ 결합 단백질
JP2014168474A (ja) * 2010-05-14 2014-09-18 Abbvie Inc Ｉｌ−１結合タンパク質
US9447184B2 (en) 2010-05-14 2016-09-20 Abbvie Inc. IL-1 binding proteins
US9409986B2 (en) 2010-05-14 2016-08-09 Abbvie Inc. IL-1 binding proteins
US9493560B2 (en) 2010-08-03 2016-11-15 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP2013537415A (ja) * 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
JP2016198102A (ja) * 2010-08-03 2016-12-01 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9085621B2 (en) 2010-09-10 2015-07-21 Apexigen, Inc. Anti-IL-1β antibodies
WO2012034039A3 (fr) * 2010-09-10 2012-07-26 Apexigen, Inc. Anticorps anti-il-1 bêta et leurs procédés d'utilisation
WO2013096516A1 (fr) 2011-12-19 2013-06-27 Xoma Technology Ltd. Méthodes de traitement de l'acné
EP3050900A1 (fr) 2011-12-19 2016-08-03 Xoma (Us) Llc Procédés pour le traitement de l'acnée
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
WO2013106547A1 (fr) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
US9045551B2 (en) 2012-11-01 2015-06-02 Abbvie Inc. Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
US9944720B2 (en) 2012-11-01 2018-04-17 Abbvie Inc. Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
US9163093B2 (en) 2012-11-01 2015-10-20 Abbvie Inc. Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
US8987418B2 (en) 2013-03-15 2015-03-24 Abbvie Inc. Dual specific binding proteins directed against IL-1β and/or IL-17
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
US10577426B2 (en) 2014-05-28 2020-03-03 Agenus Inc. Anti-GITR antibodies and methods of use thereof
EP3498295A1 (fr) 2014-05-28 2019-06-19 Agenus Inc. Anticorps anti-gitr et leurs procédés d'utilisation
US10155818B2 (en) 2014-05-28 2018-12-18 Agenus Inc. Anti-GITR antibodies and methods of use thereof
WO2015184099A1 (fr) 2014-05-28 2015-12-03 4-Antibody Ag Anticorps anti-gitr et leurs procédés d'utilisation
US10800849B2 (en) 2014-05-28 2020-10-13 Agenus Inc. Anti-GITR antibodies and methods of use thereof
US10829559B2 (en) 2014-05-28 2020-11-10 Agenus Inc. Anti-GITR antibodies and methods of use thereof
US11897962B2 (en) 2014-05-28 2024-02-13 Agenus Inc. Anti-GITR antibodies and methods of use thereof
US10280226B2 (en) 2014-05-28 2019-05-07 Agenus Inc. Anti-GITR antibodies and methods of use thereof
US11401335B2 (en) 2014-05-28 2022-08-02 Agenus Inc. Anti-GITR antibodies and methods of use thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
US9840554B2 (en) 2015-06-15 2017-12-12 Abbvie Inc. Antibodies against platelet-derived growth factor (PDGF)
US11447557B2 (en) 2015-12-02 2022-09-20 Agenus Inc. Antibodies and methods of use thereof
US10836830B2 (en) 2015-12-02 2020-11-17 Agenus Inc. Antibodies and methods of use thereof
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
US11359028B2 (en) 2016-11-09 2022-06-14 Agenus Inc. Anti-OX40 antibodies and anti-GITR antibodies
WO2020035482A1 (fr) 2018-08-13 2020-02-20 Iltoo Pharma Combinaison d'interleukine 2 et d'un inhibiteur de l'interleukine 1, conjugués et utilisations thérapeutiques de celle-ci
CN113383016B (zh) * 2018-11-07 2022-09-13 三生国健药业（上海）股份有限公司 结合人IL-1β的抗体、其制备方法和用途
CN113383016A (zh) * 2018-11-07 2021-09-10 三生国健药业（上海）股份有限公司 结合人IL-1β的抗体、其制备方法和用途

Similar Documents

Publication Publication Date Title
WO1995001997A1 (fr) ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
US7399837B2 (en) Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
JP5177444B2 (ja) Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
US6706487B1 (en) Monoclonal antibody and the method of using the antibody
JP5350793B2 (ja) 改変抗ｉｌ−２３抗体
JP4954104B2 (ja) Ｉｌ−５介在障害を治療および診断するための改良方法
US7087405B2 (en) Nucleic acids encoding anti-human ανβ3 and ανβ5 antibodies
AU695726B2 (en) Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JP2008029355A (ja) Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
SK280610B6 (sk) Monoklonálna a humanizovaná monoklonálna protilátk
AU2671699A (en) Antibodies against human cd40
US20020127227A1 (en) RHAMM antagonist antibodies
US20060263853A1 (en) Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
RU2162711C2 (ru) Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
KR100509993B1 (ko) Il-5 매개된 질환의 치료에 유용한 재조합 il-5 길항제

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 95504176

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 95504176

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 95504176

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1995504176

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1995504176

Format of ref document f/p: F